combination of a compound, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a braf v600e mutation-modulated disease or disorder and high levels of pakt in a mammal and use

摘要

The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.